Effect of Photobiomodulation as a Preventive Treatment for Diabetic Foot
Effect of Photobiomodulation as a Preventive Treatment for Diabetic Foot: Randomized Controlled Blinded Clinical Study
University of Nove de Julho
64 participants
Mar 30, 2024
INTERVENTIONAL
Conditions
Summary
This study seeks to evaluate the effect of photobiomodulation (PBM) in the prevention of Diabetic foot (DF), in patients at moderate and high risk for its development, through a controlled, randomized, double-blind clinical trial. Individuals between 18 and 75 years old of both sexes, with type 2 diabetes mellitus (DM), and moderate and high risk for DF will be randomized and allocated into 2 groups of 32 participants each. The PBM Group will use a boot with 1344 LEDs, 504 of which are 660 nm located on the sides of the boot (28.5 milliwatt, 10 J per LED); 504 850 nm also located on the sides of the boot (23 milliwatt, 8 J per LED); 168 of 660 nm located at the base of the boot (28.5 milliwatt, 10 J per LED); 168 of 850 nm also located at the base of the boot (23 milliwatt, 8 J per LED) once a day for 6 minutes, for 60 days and will receive therapeutic education. Participants will be evaluated at baseline, after 30 days (clinical examination) and after 60 days (clinical examination, Peripheral Neuropathy (PN) assessment, Peripheral Artery Disease (PAD) assessment, blood and urine tests, and quality of life).
Eligibility
Inclusion Criteria4
- Individuals diagnosed with type 2 Diabetes Mellitus (according to American Diabetes Association 2021 criteria),
- both sexes,
- between 18 and 75 years,
- Individuals classified, according to the International Working Group on the Diabetic Foot (IWGDF- 2019) scale, as moderate to high risk for developing diabetic foot,
Exclusion Criteria15
- Pregnant women
- Individuals diagnosed with type 1 diabetics,
- Individuals with neuropathy secondary to uncontrolled conditions (hypothyroidism, vitamin B12 deficiency, alcoholism),
- Individuals diagnosed with active infectious condition at the time of inclusion,
- Individuals diagnosed with active ulcer or infectious skin lesion on the legs/feet,
- Individuals with historic of osteomyelitis,
- Individuals with Parkinson's disease,
- Individuals with contracture condition,
- Individuals with severe lower limb ischemia (Fontaine III and IV - Rutherford 4 to 6),
- Individuals with a suspicious skin lesion for neoplasms or cutaneous dysplasias on the legs/feet
- Individuals diagnosed with oncologic disease or undergoing treatment within the last 3 (three) months,
- Individuals presenting unstable angina, recent acute myocardial infarction, history of severe arrhythmia within the last six months,
- Individuals diagnosed with decompensated Chronic Obstructive Pulmonary Disease (COPD),
- Inability to understand the ICF,
- Inability to attend appointments regularly.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The PBM Group will use a boot with 1344 LEDs, including 504 LEDs of 660 nm located on the sides of the boot (28.5 mW, 10 J per LED); 504 LEDs of 850 nm also located on the sides of the boot (23 mW, 8 J per LED); 168 LEDs of 660 nm located at the base of the boot (28.5 mW, 10 J per LED); and 168 LEDs of 850 nm also located at the base of the boot (23 mW, 8 J per LED) once daily for 6 minutes, over 60 days.
The Control Group will use a non-therapeutic LED boot (sham procedure) for 6 minutes once daily for 60 days. The boot used is identical to the active boot, but there is no light emission.
Participants will receive therapeutic education regarding nutrition, foot examination, self-care, and guidance on physical activity.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06353568